Approval Package / approval letter, NDA 204630 , ProvayBlue (methylene blue) injection (2016)

Government Record · Ann T. Farrell, MD, Director, Division of Hematology Products, FDA CDER · April 8, 2016

Ann T. Farrell et al., 2016-04-08: FDA approval letter granting NDA 204630 under the accelerated approval regulations for acquired methemoglobinemia, with postmarketing requirements and an orphan-drug fee exemption.

This new drug application provides for the use of ProvayBlue (methylene blue) injection for the treatment of pediatric and adult patients with acquired methemoglobinemia.

p. 1 of approval letter (PDF p. 4)

Ann T. Farrell et al., 2016-04-08: FDA approval letter granting NDA 204630 under the accelerated approval regulations for acquired methemoglobinemia, with postmarketing requirements and an orphan-drug fee exemption. C2 FDA 2016 approval record. Application dated October 9, 2015, submitted under section 505(b)(2); approved under 21 CFR 314.500 accelerated approval; letter states 'Because this drug product for this indication has an orphan drug designation, you are exempt' from a requirement; PMR 3065-2 (CYP450 DDI trial) and 3065-3 (hepatic impairment PK). text_file=A_08.txt Study type: regulatory record.